333 related articles for article (PubMed ID: 33066568)
1. Antitumor Activity of Ruthenium(II) Terpyridine Complexes towards Colon Cancer Cells In Vitro and In Vivo.
Savic M; Arsenijevic A; Milovanovic J; Stojanovic B; Stankovic V; Rilak Simovic A; Lazic D; Arsenijevic N; Milovanovic M
Molecules; 2020 Oct; 25(20):. PubMed ID: 33066568
[TBL] [Abstract][Full Text] [Related]
2. DNA binding properties, histidine interaction and cytotoxicity studies of water soluble ruthenium(ii) terpyridine complexes.
Lazić D; Arsenijević A; Puchta R; Bugarčić ŽD; Rilak A
Dalton Trans; 2016 Mar; 45(11):4633-46. PubMed ID: 26855406
[TBL] [Abstract][Full Text] [Related]
3. A new bis-pyrazolylpyridine ruthenium(III) complex as a potential anticancer drug:
Lazić D; Scheurer A; Ćoćić D; Milovanović J; Arsenijević A; Stojanović B; Arsenijević N; Milovanović M; Rilak Simović A
Dalton Trans; 2021 Jun; 50(22):7686-7704. PubMed ID: 33982702
[TBL] [Abstract][Full Text] [Related]
4. New water-soluble ruthenium(II) terpyridine complexes for anticancer activity: synthesis, characterization, activation kinetics, and interaction with guanine derivatives.
Rilak A; Bratsos I; Zangrando E; Kljun J; Turel I; Bugarčić ŽD; Alessio E
Inorg Chem; 2014 Jun; 53(12):6113-26. PubMed ID: 24884156
[TBL] [Abstract][Full Text] [Related]
5. Kinetic and mechanistic study on the reactions of ruthenium(ii) chlorophenyl terpyridine complexes with nucleobases, oligonucleotides and DNA.
Milutinović MM; Elmroth SK; Davidović G; Rilak A; Klisurić OR; Bratsos I; Bugarčić ŽD
Dalton Trans; 2017 Feb; 46(7):2360-2369. PubMed ID: 28139789
[TBL] [Abstract][Full Text] [Related]
6. New 4'-(4-chlorophenyl)-2,2':6',2″-terpyridine ruthenium(II) complexes: Synthesis, characterization, interaction with DNA/BSA and cytotoxicity studies.
Milutinović MM; Rilak A; Bratsos I; Klisurić O; Vraneš M; Gligorijević N; Radulović S; Bugarčić ŽD
J Inorg Biochem; 2017 Apr; 169():1-12. PubMed ID: 28088012
[TBL] [Abstract][Full Text] [Related]
7. Impact of aromaticity on anticancer activity of polypyridyl ruthenium(II) complexes: synthesis, structure, DNA/protein binding, lipophilicity and anticancer activity.
Čanović P; Simović AR; Radisavljević S; Bratsos I; Demitri N; Mitrović M; Zelen I; Bugarčić ŽD
J Biol Inorg Chem; 2017 Oct; 22(7):1007-1028. PubMed ID: 28695374
[TBL] [Abstract][Full Text] [Related]
8. Anti-adhesive action of novel ruthenium(II) chlorophenyl terpyridine complexes with a high affinity for double-stranded DNA: in vitro and in silico.
Masnikosa R; Milutinović MM; Crnolatac I; Tot A; Veličković S; Bojić-Trbojević Ž; Rilak-Simović A
J Inorg Biochem; 2020 Jul; 208():111090. PubMed ID: 32389890
[TBL] [Abstract][Full Text] [Related]
9. Picolinate ruthenium(II)-arene complex with in vitro antiproliferative and antimetastatic properties: comparison to a series of ruthenium(II)-arene complexes with similar structure.
Gligorijević N; Aranđelović S; Filipović L; Jakovljević K; Janković R; Grgurić-Šipka S; Ivanović I; Radulović S; Tešić ZLj
J Inorg Biochem; 2012 Mar; 108():53-61. PubMed ID: 22266461
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumour activity in non-small cell lung cancer models and toxicity profiles for novel ruthenium(II) based organo-metallic compounds.
Guichard SM; Else R; Reid E; Zeitlin B; Aird R; Muir M; Dodds M; Fiebig H; Sadler PJ; Jodrell DI
Biochem Pharmacol; 2006 Feb; 71(4):408-15. PubMed ID: 16360645
[TBL] [Abstract][Full Text] [Related]
11. Tuning the cytotoxic properties of new ruthenium(III) and ruthenium(II) complexes with a modified bis(arylimino)pyridine Schiff base ligand using bidentate pyridine-based ligands.
Garza-Ortiz A; Maheswari PU; Lutz M; Siegler MA; Reedijk J
J Biol Inorg Chem; 2014 Jun; 19(4-5):675-89. PubMed ID: 24430199
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of Ru(III) complexes carrying beta-diketonato ligands in vitro and in vivo.
Arandjelovic SS; Bjelogrlic KS; Malesevic NN; Tesic LjZ; Radulovic SS
J BUON; 2009; 14(2):271-9. PubMed ID: 19650178
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivoactivity of series of cationic dinuclearPt(II) complexes.
Vasić I; Rajković S; Arsenijević A; Milovanović M; Arsenijević N; Milovanović J; Živković MD
J Inorg Biochem; 2021 Dec; 225():111619. PubMed ID: 34597886
[TBL] [Abstract][Full Text] [Related]
14. Anticancer activity of two novel ruthenium compounds in gastric cancer cells.
Ramírez-Rivera S; Pizarro S; Gallardo M; Gajardo F; Delgadillo A; De La Fuente-Ortega E; MacDonnell FM; Bernal G
Life Sci; 2018 Nov; 213():57-65. PubMed ID: 30326218
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the In Vitro and In Vivo Efficacy of Ruthenium Polypyridyl Compounds against Breast Cancer.
Lenis-Rojas OA; Roma-Rodrigues C; Fernandes AR; Carvalho A; Cordeiro S; Guerra-Varela J; Sánchez L; Vázquez-García D; López-Torres M; Fernández A; Fernández JJ
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445620
[TBL] [Abstract][Full Text] [Related]
16. Ru
Lenis-Rojas OA; Robalo MP; Tomaz AI; Carvalho A; Fernandes AR; Marques F; Folgueira M; Yáñez J; Vázquez-García D; López Torres M; Fernández A; Fernández JJ
Inorg Chem; 2018 Nov; 57(21):13150-13166. PubMed ID: 30339386
[TBL] [Abstract][Full Text] [Related]
17. Organometallic ruthenium(II) diamine anticancer complexes: arene-nucleobase stacking and stereospecific hydrogen-bonding in guanine adducts.
Chen H; Parkinson JA; Parsons S; Coxall RA; Gould RO; Sadler PJ
J Am Chem Soc; 2002 Mar; 124(12):3064-82. PubMed ID: 11902898
[TBL] [Abstract][Full Text] [Related]
18. Increasing the bioavailability of Ru(III) anticancer complexes through hydrophobic albumin interactions.
Webb MI; Wu B; Jang T; Chard RA; Wong EW; Wong MQ; Yapp DT; Walsby CJ
Chemistry; 2013 Dec; 19(50):17031-42. PubMed ID: 24203647
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, characterization, and anticancer activity of ruthenium(II)-β-carboline complex.
Chen Y; Qin MY; Wu JH; Wang L; Chao H; Ji LN; Xu AL
Eur J Med Chem; 2013; 70():120-9. PubMed ID: 24141202
[TBL] [Abstract][Full Text] [Related]
20. Novel polypyridyl ruthenium complexes acting as high affinity DNA intercalators, potent transcription inhibitors and antitumor reagents.
Ma GL; Bi XD; Gao F; Feng Z; Zhao DC; Lin FJ; Yan R; Liu D; Liu P; Chen J; Zhang H
J Inorg Biochem; 2018 Aug; 185():1-9. PubMed ID: 29730231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
